Busulfan inhibits growth of human osteosarcoma through miR‐200 family microRNAs in vitro and in vivo
Authors:
Open Access
- 3 July 2014
- journal article
- Published by Wiley in Cancer Science
- Vol. 105 (7) , 755-762
Abstract
Osteosarcoma typically arises in tissues of mesenchymal origin, and is the most malignant bone tumor characterized by high local aggressiveness, with poor therapeutic outcome. Busulfan has been widely used to treat CML. So far, there are no reports on the therapeutic effect of busulfan on osteosarcoma. Here, we showed that busulfan dose‐dependently reduced the cell viability and proliferation, and induced cell apoptosis, senescence, and reactive oxygen species levels in two osteosarcoma cell lines. Moreover, a series of loss‐of‐function and gain‐of‐function experiments further indicated that busulfan may have its anti‐osteosarcoma effect by upregulating the microRNA‐200 (miR‐200) family which subsequently downregulated its target genes ZEB1 and ZEB2. Furthermore, treatment with busulfan potentially inhibited the growth of implanted osteosarcoma in nude mice. Taken together, our data suggest that busulfan may have an anti‐osteosarcoma effect through downregulating ZEB1 and ZEB2 through activating the miR‐200 family, highlighting a possibility of using busulfan as a novel therapy for osteosarcoma.Keywords
This publication has 23 references indexed in Scilit:
- New molecular insights into osteosarcoma targeted therapyCurrent Opinion in Oncology, 2013
- C2ORF40suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genesEpigenetics, 2013
- Pseudolaric Acid B Induced Cell Cycle Arrest, Autophagy and Senescence in Murine Fibrosarcoma L929 CellInternational Journal of Medical Sciences, 2013
- miRNA Signatures Associate with Pathogenesis and Progression of OsteosarcomaCancer Research, 2012
- Biogenesis of small RNAs in animalsNature Reviews Molecular Cell Biology, 2009
- ROS as a tumour suppressor?Nature Cell Biology, 2006
- Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma.1998
- Trypan Blue Exclusion Test of Cell ViabilityCurrent Protocols in Immunology, 1997
- Human Interferon: Mass Production in a Newly Established Cell Line, MG-63Antimicrobial Agents and Chemotherapy, 1977
- Two established in vitro cell lines from human mesenchymal tumoursInternational Journal of Cancer, 1967